Taysha Gene Therapies, Inc. (TSHA)

NMS – Real Time Price. Currency in USD

6.85

+0.03 (0.44%)

At close: May 12, 2026, 4:00 PM EDT

About the company

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Key Executives

Name	Position
Berge Minassian M.D.	Chief Medical Advisor of UT Southwestern Gene Therapy Program
Dr. Steven Gray Ph.D.	Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Dr. Sukumar Nagendran M.D.	President, Head of Research & Development and Director
Hayleigh Collins	Director of Corporate Communications & Investor Relations
Mr. Frederick Porter Ph.D.	Chief of Staff & Technical Operations Officer
Mr. Kamran Alam CPA, M.B.A.